EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY-NC 4.0

Durability of the Blood Pressure Effects of Renal Pelvic Denervation in Patients with Hypertension during a 12-Month Observation

Michael A Weber, Dagmara Hering, David Nikoleishvili, Avtandil Imedadze, Gvantsa Dughashvili, Zurab Klimiashvili, Eter Bekaia, Tamar Shengelia, Mamuka Kabalava, Otar Goguadze, Tamar Emukhvari, Vitaly Druker und 4 weitere

American Journal of Nephrology · 2024

DOI: 10.1159/000533569 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Michael A Weber und 15 weiteren Autor:innen. Beteiligte Einrichtung: Downstate Medical Center, State University of New York, Brooklyn, New York, USA. Hauptthemen laut MEDLINE: Hypertension, Blood Pressure, Blood Pressure Monitoring, Ambulatory. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We previously completed a trial of renal pelvic denervation for treating hypertension that reduced blood pressure by the 2-month primary endpoint. However, information on the durability of effectiveness is a critical requirement for device therapy and we now report data up to 12 months.

Methods

This was an open-label, single-arm feasibility study in patients with increased blood pressure despite taking an average of 2.7 medications. The key endpoint reported here was ambulatory blood pressure at 12 months following renal pelvic denervation.

Results

In the 17 patients (mean age: 56) studied, there was a reduction from the baseline of 148 + 8.7 mm Hg in the primary endpoint of mean daytime systolic blood pressure at 12 months of 19.1 (26.7, 11.6) mm Hg, p < 0.001, as compared with the 2-month result of 19.4 (24.9, 14.0) mm Hg. The 24-h systolic blood pressure fell by 19.3 (26.7, 11.9), p < 0.001, and nighttime systolic fell by 18.7 (27.5, 9.8), p < 0.001, mm Hg at 12 months. Diastolic pressures also fell significantly from baseline at 12 months. As well, automated office systolic blood pressure was reduced from the baseline of 156.5 ± 12.3 by 24.8 (33.2, 16.8) mm Hg, p < 0.001, at 12 months as compared with 22.4 (31.5, 13.3) at 2 months. All blood pressure changes at 12 months were not different from those at 2 months, thus confirming the durability of the procedure. There were no serious procedural, clinical, or laboratory adverse events related to the intervention. Serum creatinine fell from 1.03 ± 0.22 to 0.82 ± 0.16 mg/dL, and estimated glomerular filtration rate rose from 79.6 ± 17.8 to 96.3 ± 16.4 mL/min/1.73 m2 by 12 months, again sustaining effects seen at 2 months.

Conclusion

These findings provide evidence that the significant blood pressure-lowering effects of renal pelvic denervation are durable and safe for at least 1 year and provide the basis for a pivotal randomized blinded trial to further define the safety and effectiveness of this procedure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionBlood PressureBlood Pressure Monitoring, AmbulatoryHumansMiddle AgedFemaleMaleAgedKidney PelvisFeasibility StudiesTreatment OutcomeAdultSympathectomyKidneyTime Factors

Stichwörter der Autor:innen

Renal denervationRenal pelvisTrans-ureteralUncontrolled hypertension

Autor:innen und Institutionen

  • Downstate Medical Center, State University of New York, Brooklyn, New York, USA.
  • College of Health Solutions, Arizona State University, Phoenix, Arizona, USA.
  • Department of Hypertension and Diabetology, Medical University of Gdansk, Gdansk, Poland.
  • Israeli-Georgian Medical Research Clinic Helsicore, Tbilisi, Georgia.
  • Pineo Medical Ecosystem, Tbilisi, Georgia.
  • West End Statistics, LLC, New York, New York, USA.

Zitieren

APA

Weber, M. A., Hering, D., Nikoleishvili, D., Imedadze, A., Dughashvili, G., Klimiashvili, Z., Bekaia, E., Shengelia, T., Kabalava, M., Goguadze, O., Emukhvari, T., Druker, V., Buelna, T., Heuser, R., Hashemian, S., & Provanzano, R. (2024). Durability of the Blood Pressure Effects of Renal Pelvic Denervation in Patients with Hypertension during a 12-Month Observation. American Journal of Nephrology. https://doi.org/10.1159/000533569

Vancouver

Weber MA, Hering D, Nikoleishvili D, Imedadze A, Dughashvili G, Klimiashvili Z, et al. Durability of the Blood Pressure Effects of Renal Pelvic Denervation in Patients with Hypertension during a 12-Month Observation. American Journal of Nephrology. 2024. doi:10.1159/000533569

BibTeX
@article{Weber2024,
  author = {Weber, Michael A and Hering, Dagmara and Nikoleishvili, David and Imedadze, Avtandil and Dughashvili, Gvantsa and Klimiashvili, Zurab and Bekaia, Eter and Shengelia, Tamar and Kabalava, Mamuka and Goguadze, Otar and Emukhvari, Tamar and Druker, Vitaly and Buelna, Terry and Heuser, Richard and Hashemian, Shima and Provanzano, Robert},
  title = {Durability of the Blood Pressure Effects of Renal Pelvic Denervation in Patients with Hypertension during a 12-Month Observation},
  journal = {American Journal of Nephrology},
  year = {2024},
  doi = {10.1159/000533569}
}
Kostenlos starten →